Tag: Medicare
Aduhelm, a drug developed recently by Biogen, has raised enormously important issues for Medicare. Biogen’s initial proposed price for Aduhelm was $56,000 per patient per year. Because Aduhelm is administered intravenously by physicians, it would be covered under Medicare Part B. (Medicare Part D covers retail prescription drugs.) While, to date, Medicare has covered virtually…
It’s always worth taking a look at the finances of Medicare, given its contribution to the health and well-being of older Americans and its dependence on the payroll tax – the key source of revenue for Social Security. The topic is much more exciting – and frightening – in the wake of Aduhelm – a…
